Investment report on Array BioPharma

Apr 21 2010

MicroStockProfit.com announces an investment report featuring Array BioPharma Inc. (Nasdaq:ARRY). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/ads/ARRY

Array BioPharma Inc. (ARRY) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. In addition, pharmaceutical and biotechnology companies collaborate with the Company to discover and develop drug candidates across a range of therapeutic areas. The Company has seven wholly owned programs in its development pipeline: ARRY-403, a glucokinase activator for type 2 diabetes; ARRY-162, a MEK inhibitor for rheumatoid arthritis and cancer; ARRY-380, an ErbB-2 inhibitor for breast cancer; ARRY-520, a KSP inhibitor for acute myeloid leukemia and multiple myeloma; ARRY-614, a p38/Tie 2 dual inhibitor for myelodysplastic syndrome; ARRY-543, an ErbB family (ErbB-2 / EGFR) inhibitor for solid tumors, and ARRY-797, a p38 inhibitor for subacute pain and cancer supportive care indications.

Message Board Search for ARRY: http://www.boardcentral.com/boards/ARRY

In the report, the analyst notes:

"ARRY shares were boosted after the Company's recent announcement that it licensed a group of experimental cancer treatments to drugmaker Novartis, an agreement that ARRY CEO Robert Conways calls a major advance in the Company's 'strategic objective to become a fully integrated, commercial-stage biopharmaceutical company.'

"Under the terms of the deal, ARRY will initially receive $45 million comprising an upfront and milestone payment and is eligible to receive an additional $422 million if certain clinical, regulatory and commercial milestones are achieved."